Zydus Lifesciences launches Anyra for advancing ophthalmic care

Zydus Lifesciences has launched Anyra, India’s first indigenously developed biosimilar of Aflibercept 2 mg. The company has also signed an agreement with Regeneron Pharmaceuticals, Inc. and Bayer. Anyra is indicated for the treatment of neovascular (wet) Age-related Macular Degeneration (AMD), visual impairment due to macular edema secondary to Retinal Vein Occlusion (Branch RVO or Central RVO), visual impairment due to Diabetic Macular Edema (DME), Diabetic Retinopathy (DR), and visual impairment due to Myopic Choroidal Neovascularization (mCNV). With this launch, the company reinforces its commitment to advancing ophthalmic care and expanding access to high-quality, affordable biologics for patients across India.

Zydus Lifesciences (formerly known as Cadila Healthcare), a company limited by shares, incorporated and domiciled in India, operates as an integrated pharmaceutical company with business encompassing the entire value chain in the research, development, production, marketing and distribution of pharmaceutical products.